Trade Vor Biopharma Inc. - VOR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.67 |
| Open | 0.68 |
| 1-Year Change | -59.04% |
| Day's Range | 0.62 - 0.68 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 21, 2025 | 0.67 | 0.02 | 3.08% | 0.65 | 0.68 | 0.64 |
| Apr 17, 2025 | 0.62 | -0.01 | -1.59% | 0.63 | 0.66 | 0.61 |
| Apr 16, 2025 | 0.63 | -0.03 | -4.55% | 0.66 | 0.66 | 0.62 |
| Apr 15, 2025 | 0.67 | -0.01 | -1.47% | 0.68 | 0.70 | 0.66 |
| Apr 14, 2025 | 0.68 | -0.02 | -2.86% | 0.70 | 0.71 | 0.64 |
| Apr 11, 2025 | 0.66 | 0.06 | 10.00% | 0.60 | 0.66 | 0.60 |
| Apr 10, 2025 | 0.60 | 0.01 | 1.69% | 0.59 | 0.61 | 0.55 |
| Apr 9, 2025 | 0.55 | 0.02 | 3.77% | 0.53 | 0.56 | 0.47 |
| Apr 8, 2025 | 0.53 | -0.01 | -1.85% | 0.54 | 0.58 | 0.53 |
| Apr 7, 2025 | 0.52 | -0.01 | -1.89% | 0.53 | 0.54 | 0.49 |
| Apr 4, 2025 | 0.55 | -0.03 | -5.17% | 0.58 | 0.58 | 0.53 |
| Apr 3, 2025 | 0.57 | -0.02 | -3.39% | 0.59 | 0.59 | 0.55 |
| Apr 2, 2025 | 0.61 | 0.00 | 0.00% | 0.61 | 0.62 | 0.60 |
| Apr 1, 2025 | 0.60 | -0.09 | -13.04% | 0.69 | 0.70 | 0.60 |
| Mar 31, 2025 | 0.69 | -0.05 | -6.76% | 0.74 | 0.74 | 0.68 |
| Mar 28, 2025 | 0.73 | -0.01 | -1.35% | 0.74 | 0.75 | 0.73 |
| Mar 27, 2025 | 0.74 | -0.05 | -6.33% | 0.79 | 0.79 | 0.73 |
| Mar 26, 2025 | 0.79 | -0.05 | -5.95% | 0.84 | 0.84 | 0.78 |
| Mar 25, 2025 | 0.82 | -0.06 | -6.82% | 0.88 | 0.89 | 0.81 |
| Mar 24, 2025 | 0.86 | 0.04 | 4.88% | 0.82 | 0.87 | 0.81 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Vor Biopharma Inc. Company profile
About Vor Biopharma Inc
Vor Biopharma Inc is a clinical-stage cell therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solution for patients suffering from hematological malignancies. The Company develops engineered hematopoietic stem cell (eHSC) product candidate, VOR33, VCAR33, which together are the treatment paradigm for acute myeloid leukemia (AML) and other hematological malignancies. The Company’s platform provides treatment for both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates (ADCs), bispecific antibodies and CAR-T cell treatments, including CD33 CAR-T. The Company uses genome engineering technology to remove CD33 surface targets from hematopoietic stem cells (HSCs) to create VOR33. The Company’s eHSCs, such as VOR33, are designed to be used with therapeutics such as VCAR33, that would provide tumor-specific killing.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Vor Biopharma Inc revenues was not reported. Net loss applicable to common stockholders increased 65% to $51.9M. Higher net loss reflects Research and development - Balancing val increase of 67% to $33.2M (expense), General and administrative - Balancing increase from $7M to $14.4M (expense), Stock-based Compensation in R&D increase from $374K to $1.6M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
100 Cambridgepark Drive
Suite 101
CAMBRIDGE
MASSACHUSETTS 02140
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com